- Clone
- W21076A (See other available formats)
- Regulatory Status
- RUO
- Other Names
- CD272, B- and T-lymphocyte attenuator, B- and T-lymphocyte-associated protein
- Isotype
- Rat IgG2b, κ
-
Biotinylated recombinant human BTLA-Fc chimera (Cat. No. 794904) (black circles) binds to immobilized recombinant mouse HVEM-Fc chimera (Cat. No. 771304). Ultra-LEAF™ purified anti-human CD272 (BTLA) (clone W21076A) (purple squares) inhibits this binding in a dose-dependent manner, whereas the Ultra-LEAF™ purified rat IgG2b, κ isotype control (Cat. No. 400644) (gray triangles) does not have this effect. ND50 range: 4-30 ng/mL
| Cat # | Size | Price | Quantity Check Availability | ||
|---|---|---|---|---|---|
| 622053 | 100 µg | $345.00 | |||
| 622054 | 1 mg | $1205.00 | |||
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
BTLA (B and T lymphocyte attenuator, CD272) is a type I transmembrane glycoprotein with four extracellular cysteine-rich domains. It is an inhibitory molecule structurally and functionally similar to cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1). These molecules belong to the immunoglobulin superfamily that binds B7 family members. Different from CTLA-4 and PD-1 binding with the B7 family members, BTLA interacts with herpes virus entry mediator (HVEM/TNFRSF14) which belongs to TNFR family. BTLA/HVEM interaction was the first demonstration of crosstalk between these two family members. BTLA/HVEM interaction limits T cell activity in vivo and regulates the homeostatic expansion of CD4+ and CD8+ T cells. BTLA/HVEM interaction negatively modulates T cell activation. HVEM induces BTLA tyrosine phosphorylation and inhibits T-cell proliferation. There is accumulating evidence suggesting that BTLA/HVEM signaling also plays an important role in autoimmunity and infection at mucosal surfaces. The BTLA/HVEM interaction does not prevent the simultaneous binding of other HVEM ligands such as LIGHT/TNFSF14 or Lymphotoxin-alpha. BTLA is expressed on T cells, B cells, macrophages, dendritic cells, and natural killer cells. Constitutive expression level of BTLA on resting T cells are very low, but increase after the activation of T cells. BTLA is highly expressed on resting B cells.
Product Details
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Recombinant human CD272 (BTLA)
- Formulation
- 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
- Preparation
- The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
- Concentration
- The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
- Application
-
Block - Quality tested
- Recommended Usage
-
Each lot of this antibody is quality control tested by blocking the binding of 0.007 µg/mL biotinylated recombinant human BTLA-Fc chimera to 0.05 µg/mL immobilized recombinant mouse HVEM-Fc chimera. ND50 range: 4-30 ng/mL. It is recommended that the reagent be titrated for optimal performance for each application.
- RRID
-
AB_3097232 (BioLegend Cat. No. 622053)
AB_3097232 (BioLegend Cat. No. 622054)
Antigen Details
- Structure
- Disulfide bond-linked homodimer
- Distribution
-
Expressed in activated B, T (activated, memory), Th1, Th2 and Th17 Effector T-cells of patients with systemic lupus erythematosus, dendritic cells, macrophages, and hematopoietic stem cells
- Function
- B cell co-stimulation, proliferation and Ig production, limits T cell activity in vivo and homeostatic expansion of CD4+ and CD8+ T cells, NKT differentiation
- Interaction
- Lymphocytes
- Ligand/Receptor
- HVEM (TNFRSF14)
- Cell Type
- B cells, Dendritic cells, NK cells, T cells, Tregs
- Biology Area
- Immunology, Inhibitory Molecules
- Molecular Family
- CD Molecules
- Antigen References
-
- Gavrieli M, et al. 2003. Biochem. Biophys Res Commun. 312:1236-43.
- Gonzalez LC, et al. 2005. Proc Natl Acad. Sci. USA. 102:1116.
- Sedy JR, et al. 2005. Nat Immunol. 6:90-8.
- Kronenberg KM, et al. 2009. Proc Natl Acad Sci USA. 106:6244.
- Shui JW, et al. 2011. J Leukoc Biol. 89:517-23.
- Ofter C, et al. 2019. Int J Mol Sci. 20:4505.
- Yu X, et al. 2019. Front Immunol. 10: 617.
- Gene ID
- 151888 View all products for this Gene ID
- UniProt
- View information about CD272 on UniProt.org
Other Formats
View All CD272 Reagents Request Custom Conjugation| Description | Clone | Applications |
|---|---|---|
| Ultra-LEAF™ Purified anti-human CD272 (BTLA) | W21076A | Block |
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
-
Ultra-LEAF™ Purified anti-human CD272 (BTLA)
Biotinylated recombinant human BTLA-Fc chimera (Cat. No. 794...